Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

351.16 -3.65 (-1.03%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,135,105
Open 355.11
Bid (Size) 348.56 (1)
Ask (Size) 353.00 (1)
Prev. Close 354.81
Today's Range 350.23 - 356.71
52wk Range 282.21 - 387.42
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 No-Brainer Growth Stocks to Buy in December
No analysis paralysis is required with these great stocks. 
Via The Motley Fool
Got $5,000? These Are 2 of the Best Growth Stocks to Buy Right Now
The one thing these two stocks have in common is tremendous growth prospects. 
Via The Motley Fool

Performance

YTD
+22.77%
+22.77%
1 Month
-6.74%
-6.74%
3 Month
+0.83%
+0.83%
6 Month
+5.01%
+5.01%
1 Year
+9.27%
+9.27%

More News

Read More
5 Top Stocks to Buy Before 2024
Via The Motley Fool
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Via The Motley Fool
Looking for Growth? 2 Top Stocks to Buy Hand Over Fist
Via The Motley Fool
3 Biotech Stocks That Could Be Multibaggers in the Making
Via InvestorPlace
3 Top-Rated Biotech Stocks That Analysts Are Loving Now
Via InvestorPlace
Biotech And Healthcare Portfolio Playbook For December 2023/24
Via Talk Markets
5 Stocks You Can Confidently Invest $500 In Right Now
Via The Motley Fool
2 Healthcare Stocks That Could Help Set You Up for Life
Via The Motley Fool
Investing in These 3 Stocks Now Could Make You a Millionaire Retiree
Via The Motley Fool
4 First-Class Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Via The Motley Fool
Topics Stocks
Exposures US Equities
European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Prediction: 3 Stocks That Could Trounce the Market
Via The Motley Fool
3 Biotech Stocks That Could Be Millionaire Makers
Via The Motley Fool
Here's How Much $100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth Today
Via Benzinga
2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street
Via The Motley Fool
Could Investing $10,000 In CRISPR Therapeutics Stock Make You a Millionaire?
Via The Motley Fool
Barron's Weekend Stock Picks: Disney, Palantir And Cisco's Calamitous Outlook
Via Benzinga
Why CRISPR Therapeutics Stock Is Jumping Again Today
Via The Motley Fool
Williams-Sonoma, Uber And 2 Other Stocks Insiders Are Selling
Via Benzinga
InvestorNewsBreaks – Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Featured in Barron’s Article for Potential Near ‘Breakthrough’
Via Investor Brand Network
Crispr Surges After Winning The First-Ever Approval For A CRISPR-Based Gene-Editing Drug
Via Investor's Business Daily
What's Going On With Crispr Therapeutics Stock Thursday?
Via Benzinga
CRISPR Therapeutics (CRSP) Stock Jumps as U.K. Authorizes Gene Therapy
Via InvestorPlace
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.